What is the quality and effectiveness of rasagiline produced by Qilu Pharmaceutical?

Rasagiline mesylate tablets (trade name: Leilan) produced by Qilu Pharmaceutical are the domestically approved generic version of rasagiline. Its main indication is the treatment of Parkinson's disease. It is especially suitable for early symptom control or combined with levodopa for the management of the "switch phenomenon" in the middle and late stages.

As a domestic generic drug, Leilan is produced in strict accordance with the quality consistency evaluation standards of the National Center for Drug Evaluation. The quality control, production process, and stability testing of raw materials and excipients must meet the same pharmaceutical and clinical requirements as the original drug. According to public information, Qilu Pharmaceutical has strong technical reserves and industrial chain integration capabilities in the development of generic drugs. The rasagiline it produces has been verified by bioequivalence studies and has no significant difference in absorption, distribution and metabolism characteristics with the original drug in the human body. Therefore, the therapeutic effects can be basically treated equally.

The clinical application feedback of Rasagiline is generally good, and patients have shown a certain degree of compliance and satisfaction with its improvement in typical Parkinson's symptoms such as bradykinesia, tremor, and muscle stiffness during use. In combination with levodopa treatment, it can also significantly prolong the "onset" time and reduce the end-of-dose effect. Compared with imported original drugs, the price of Leilan is more advantageous, which reduces the financial burden for Parkinson's disease patients who take long-term medication. Especially after being included in medical insurance, the monthly treatment expenses of some patients are significantly reduced, improving drug accessibility.

It should be pointed out that although generic drugs are equivalent to the original drugs in terms of effectiveness and safety, they may still have slightly different efficacy due to individual differences. Patients should flexibly adjust the dosage according to clinical response under the guidance of a professional doctor.

Reference materials:https://www.azilect.com/